Literature DB >> 7118244

Virus-specific antibodies in sera from patients with genital herpes simplex virus infection.

H J Zweerink, L Corey.   

Abstract

Virus-specific antibodies against a number of herpes simplex virus type 2 antigens were determined by radioimmunoprecipitation assays in sequential serum samples obtained from 12 patients with initial genital herpes simplex virus infection. The progressive appearance of antibodies to virus-specific antigens was observed; antibodies against a 130,000-molecular-weight glycoprotein complex appeared first, followed by antibodies against the major nucleocapsid polypeptide and then antibodies against a number of other viral antigens, including a polypeptide with a molecular weight of 62,000. Patients who developed a wide variety of antibodies to viral polypeptides shortly after resolution of their initial episode seemed to experience more severe initial infections and more recurrences than did those who reacted poorly with these virus-specific antigens. This was most apparent with respect to antibodies to virus-specific polypeptides with molecular weights between 30,000 and 43,000. Antibody specificity did not change during the course of follow-up regardless of whether serum samples were taken shortly before, during, or after recurrent episodes. Glycoprotein-specific antibodies were quantitated with the purified 130,000-molecular-weight glycoprotein material. No significant fluctuations in these antibody titers were observed before or after recurrences of the disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7118244      PMCID: PMC347549          DOI: 10.1128/iai.37.2.413-421.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

Review 1.  Herpes simplex infections in hematologic malignancies.

Authors:  S A Muller; E C Herrmann; R K Winkelmann
Journal:  Am J Med       Date:  1972-01       Impact factor: 4.965

2.  Herpesviruses in renal transplant patients.

Authors:  F D Pien; T F Smith; C F Anderson; M L Webel; H F Taswell
Journal:  Transplantation       Date:  1973-11       Impact factor: 4.939

3.  Isolation of viruses, bacteria and other organisms from venereal disease clinic patients: methodology and problems associated with multiple isolations.

Authors:  B B Wentworth; P Bonin; K K Holmes; L Gutman; P Wiesner; E R Alexander
Journal:  Health Lab Sci       Date:  1973-04

4.  Herpesvirus hominis infection in patients with myeloproliferative and lymphoproliferative disorders.

Authors:  D L Aston; A Cohen; M A Spindler
Journal:  Br Med J       Date:  1972-11-25

5.  Seroepidemiology of infectious due to members of the herpesvirus group.

Authors:  B B Wentworth; E R Alexander
Journal:  Am J Epidemiol       Date:  1971-11       Impact factor: 4.897

6.  A useful quantitative semimicromethod for viral plaque assay.

Authors:  B Rager-Zisman; T C Merigan
Journal:  Proc Soc Exp Biol Med       Date:  1973-04

7.  Proteins specified by herpes simplex virus. V. Purification and structural proteins of the herpesvirion.

Authors:  P G Spear; B Roizman
Journal:  J Virol       Date:  1972-01       Impact factor: 5.103

8.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

9.  Antibodies to Herpesvirus hominis types 1 and 2 in humans. I. Patients with genital herpetic infections.

Authors:  A J Nahmias; W E Josey; Z M Naib; C F Luce; A Duffey
Journal:  Am J Epidemiol       Date:  1970-06       Impact factor: 4.897

10.  Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response.

Authors:  W C Reeves; L Corey; H G Adams; L A Vontver; K K Holmes
Journal:  N Engl J Med       Date:  1981-08-06       Impact factor: 91.245

View more
  6 in total

1.  Human antibody response to herpes simplex virus-specific polypeptides after primary and recurrent infection.

Authors:  J Kahlon; F D Lakeman; M Ackermann; R J Whitley
Journal:  J Clin Microbiol       Date:  1986-04       Impact factor: 5.948

2.  Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.

Authors:  W D Hunter; R L Martuza; F Feigenbaum; T Todo; T Mineta; T Yazaki; M Toda; J T Newsome; R C Platenberg; H J Manz; S D Rabkin
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

3.  A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G.

Authors:  I Frank; H M Friedman
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

4.  Detection of type-specific antibody to herpes simplex virus type 1 by radioimmunoassay with herpes simplex virus type 1 glycoprotein C purified with monoclonal antibody.

Authors:  A M Arvin; C M Koropchak; A S Yeager; L Pereira
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

5.  Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine.

Authors:  R Ashley; G Mertz; H Clark; M Schick; D Salter; L Corey
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

6.  Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.

Authors:  Joshua J Geltz; Edward Gershburg; William P Halford
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.